Lerato Mohapi to HIV-Associated Lipodystrophy Syndrome
This is a "connection" page, showing publications Lerato Mohapi has written about HIV-Associated Lipodystrophy Syndrome.
Connection Strength
0,138
-
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 01; 4(1):e13-e20.
Score: 0,138